16
Participants
Start Date
June 30, 2005
Primary Completion Date
October 31, 2012
Study Completion Date
March 31, 2013
cyclophosphamide
1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
doxorubicin hydrochloride
25mg/m²/day, 2 hours i.v.infusion on day 21
etoposide
150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
prednisone
40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
vinblastine sulfate
6 mg/m² i.v. bolus on day 1 and day 21
vincristine sulfate
1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
radiation therapy
involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
Kinderklinik d. TU / Schwabing, Munich
Universitaets - Kinderklinik, Erlangen
Klinikum Augsburg, Augsburg
Charite University Medical Center of Berlin, Berlin
Medizinische Universitaetsklinik I at the University of Cologne, Cologne
Universitaetsfrauenklinik Frankfurt, Frankfurt
Universitaetsklinikum Halle, Halle
Medizinische Hochschule Hannover, Hanover
Universitaets - Kinderklinik, Leipzig
Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster, Münster
Klinikum Oldenburg, Oldenburg
University Children's Hospital, Zurich
Martin-Luther-Universität Halle-Wittenberg
OTHER
Christine Mauz-Körholz
OTHER